Needham Maintains Buy on NeoGenomics, Raises Price Target to $19
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Needham analyst Mike Matson maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price target from $15 to $19.
Needham analyst Mike Matson maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price target from $15 to $19.